• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Hims & Hers Taps Digital Pharmacy Alto for Same-day Medication Deliveries

Share:

August 5, 2020

D2C wellness and telehealth startup Hims & Hers is looking to cut down the time between medication orders and delivery for certain customers.

Thanks to a newly announced partnership, patients receiving virtual primary care services through Hims & Hers may choose to select Alto as their preferred pharmacy for prescription deliveries. They will have their orders fulfilled automatically through the digital pharmacy and receive free, same-day receipt of their medications.

Customers will also receive access to Alto’s patient app, which lets them: set preferred times for home delivery, review medication payment info, text-chat with pharmacists and receive medication reminders.

The arrangement is only available to Hims & Hers users in the San Francisco Bay Area, Los Angeles, Orange County, Seattle, Las Vegas and the Denver-Boulder area.

WHAT’S THE IMPACT?

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Hims & Hers carved out its niche in the wellness space by stressing ease of access for its mail-order goods. A partner that can provide immediate delivery and support for more complicated medications – at no additional charge to the consumer – will help the brand reinforce those strengths as it looks to make a dent in the virtual care market. Alto, meanwhile, will likely see a new influx of users enter its own ecosystem.

“Hims & Hers is a natural partner to Alto’s courier-based platform,” Melissa Baird, COO of Hims & Hers, said in a statement. “We’re excited to work with Alto to bring the ease and convenience of their same-day delivery experience to those using Hims & Hers to access primary care services.”

The arrangement also comes at a time when social distancing and quarantines are driving new demand for virtual care services. Greater access to expedited the home delivery of medications could play a role in limiting COVID-19 exposure for chronic-disease patients and others at risk of poor outcomes.

THE LARGER TREND

Founded in 2015 as ScriptDash, Alto’s digital pharmacy was very well funded prior to the outbreak, having raised a total of more than $350 million early this year for a valuation of over $1 billion. Other players in the same-day medication delivery space include NowRx and Medly, both of which saw their own recent funding rounds.

Hims & Hers was trending upward prior to COVID-19, but has since found new opportunities to grow the virtual care side of its business with new service offerings. The brand is also rumored to have a $1 billion valuation. It appears to be investigating a deal that would bring its business to the public markets. Its primary competitor, Ro, recently raised $200 million for a $1.5 billion valuation.

ON THE RECORD

“At Alto, we’re constantly looking for new ways to improve the healthcare and pharmacy experience, and we’re excited to partner with Hims & Hers to offer free, same-day courier medication delivery for their patients,” Omar Nagji, VP of enterprise at Alto Pharmacy, said in a statement. “Our partnership with Hims & Hers offers patients control, discretion and pharmacist access without making a trip to a doctor’s office or pharmacy.”

Source: Mobihealth News

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Healthcare SaaS Startup GrowthPlug Secures $1 Million Investment from Elevate CapitalHealthcare SaaS Startup GrowthPlug Secures $1 Million Investment from Elevate Capital
  • Q Bio Raises $40 Million Series B Led By Andreessen Horowitz to Bring Preventative Health and the Physical of the Future to MassesQ Bio Raises $40 Million Series B Led By Andreessen Horowitz to Bring Preventative Health and the Physical of the Future to Masses
  • OncoTracker Expands Multiple Myeloma Intellectual PropertyOncoTracker Expands Multiple Myeloma Intellectual Property
  • Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference CallProvention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
  • Mylan Acquires Aspen’s European Thrombosis Portfolio for $757.3 MillionMylan Acquires Aspen’s European Thrombosis Portfolio for $757.3 Million
  • Bausch Health’s Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)Bausch Health’s Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)
  • Discord Within Apple’s Health Team, Benefits From Brain Training Games And More Digital Health News BriefsDiscord Within Apple’s Health Team, Benefits From Brain Training Games And More Digital Health News Briefs
  • CareDx Absorbs Transplant Hero to Build Out Post-Organ Transplant Services

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications